ID   HIF1A_RAT               Reviewed;         825 AA.
AC   O35800; Q9WTU9;
DT   03-JUL-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   29-MAY-2024, entry version 199.
DE   RecName: Full=Hypoxia-inducible factor 1-alpha;
DE            Short=HIF-1-alpha;
DE            Short=HIF1-alpha;
GN   Name=Hif1a;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Wistar; TISSUE=Hepatocyte;
RX   PubMed=11237857; DOI=10.1042/0264-6021:3540531;
RA   Kietzmann T., Cornesse Y., Brechtel K., Modaressi S., Jungermann K.;
RT   "Perivenous expression of the mRNA of the three hypoxia-inducible factor a-
RT   subunits HIF-1a, HIF2a and HIF3a in rat liver.";
RL   Biochem. J. 354:531-537(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Kidney;
RX   PubMed=11526200; DOI=10.1152/physiolgenomics.2001.6.3.159;
RA   Zou A.-P., Yang Z.-Z., Li P.-L., Cowley A.W. Jr.;
RT   "Oxygen-dependent expression of hypoxia-inducible factor-1alpha in renal
RT   medullary cells of rats.";
RL   Physiol. Genomics 6:159-168(2001).
CC   -!- FUNCTION: Functions as a master transcriptional regulator of the
CC       adaptive response to hypoxia. Under hypoxic conditions, activates the
CC       transcription of over 40 genes, including erythropoietin, glucose
CC       transporters, glycolytic enzymes, vascular endothelial growth factor,
CC       HILPDA, and other genes whose protein products increase oxygen delivery
CC       or facilitate metabolic adaptation to hypoxia. Plays an essential role
CC       in embryonic vascularization, tumor angiogenesis and pathophysiology of
CC       ischemic disease (By similarity). Heterodimerizes with ARNT;
CC       heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia
CC       response element (HRE) of target gene promoters (By similarity).
CC       Activation requires recruitment of transcriptional coactivators such as
CC       CREBBP and EP300. Activity is enhanced by interaction with NCOA1 and/or
CC       NCOA2. Interaction with redox regulatory protein APEX1 seems to
CC       activate CTAD and potentiates activation by NCOA1 and CREBBP. Involved
CC       in the axonal distribution and transport of mitochondria in neurons
CC       during hypoxia (By similarity). {ECO:0000250|UniProtKB:Q16665,
CC       ECO:0000250|UniProtKB:Q61221}.
CC   -!- ACTIVITY REGULATION: Induced by reactive oxygen species (ROS).
CC       {ECO:0000250|UniProtKB:Q16665}.
CC   -!- SUBUNIT: Interacts with the ARNT; forms a heterodimer that binds core
CC       DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of
CC       target gene promoters (By similarity). Interacts with COPS5; the
CC       interaction increases the transcriptional activity of HIF1A through
CC       increased stability (By similarity). Interacts with EP300 (via TAZ-type
CC       1 domains); the interaction is stimulated in response to hypoxia and
CC       inhibited by CITED2. Interacts with CREBBP (via TAZ-type 1 domains).
CC       Interacts with NCOA1, NCOA2, APEX1 and HSP90. Interacts (hydroxylated
CC       within the ODD domain) with VHLL (via beta domain); the interaction,
CC       leads to polyubiquitination and subsequent HIF1A proteasomal
CC       degradation. During hypoxia, sumoylated HIF1A also binds VHL; the
CC       interaction promotes the ubiquitination of HIF1A (By similarity).
CC       Interacts with SENP1; the interaction desumoylates HIF1A resulting in
CC       stabilization and activation of transcription (By similarity).
CC       Interacts (via the ODD domain) with NAA10; the interaction appears not
CC       to acetylate HIF1A nor have any affect on protein stability, during
CC       hypoxia. Interacts with RWDD3; the interaction enhances HIF1A
CC       sumoylation (By similarity). Interacts with TSGA10. Interacts with
CC       HIF3A (By similarity). Interacts with RORA (via the DNA binding
CC       domain); the interaction enhances HIF1A transcription under hypoxia
CC       through increasing protein stability. Interaction with PSMA7 inhibits
CC       the transactivation activity of HIF1A under both normoxic and hypoxia-
CC       mimicking conditions. Interacts with USP20. Interacts with RACK1;
CC       promotes HIF1A ubiquitination and proteasome-mediated degradation.
CC       Interacts (via N-terminus) with USP19. Interacts with SIRT2. Interacts
CC       (deacetylated form) with EGLN1. Interacts with CBFA2T3. Interacts with
CC       HSP90AA1 and HSP90AB1. Interacts with DCUN1D1; this interaction
CC       increases the interaction between VHL and DCUN1D1. Interacts with
CC       HIF1AN (By similarity). {ECO:0000250|UniProtKB:Q16665,
CC       ECO:0000250|UniProtKB:Q61221}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q16665}.
CC       Nucleus. Nucleus speckle {ECO:0000250|UniProtKB:Q61221}.
CC       Note=Colocalizes with HIF3A in the nucleus and speckles (By
CC       similarity). Cytoplasmic in normoxia, nuclear translocation in response
CC       to hypoxia (By similarity). {ECO:0000250|UniProtKB:Q16665,
CC       ECO:0000250|UniProtKB:Q61221}.
CC   -!- TISSUE SPECIFICITY: Expressed in the kidney, higher expression is seen
CC       in the renal medulla than in the cortex. Expressed also in the
CC       perivenous zone of the liver.
CC   -!- DOMAIN: Contains two independent C-terminal transactivation domains,
CC       NTAD and CTAD, which function synergistically. Their transcriptional
CC       activity is repressed by an intervening inhibitory domain (ID) (By
CC       similarity). {ECO:0000250|UniProtKB:Q16665}.
CC   -!- PTM: S-nitrosylation of Cys-799 may be responsible for increased
CC       recruitment of p300 coactivator necessary for transcriptional activity
CC       of HIF-1 complex. {ECO:0000250|UniProtKB:Q16665}.
CC   -!- PTM: Acetylation of Lys-531 by ARD1 increases interaction with VHL and
CC       stimulates subsequent proteasomal degradation. Deacetylated by SIRT2
CC       increases its interaction with and hydroxylation by EGLN1 thereby
CC       inactivating HIF1A activity by inducing its proteasomal degradation (By
CC       similarity). {ECO:0000250|UniProtKB:Q16665}.
CC   -!- PTM: Ubiquitinated; in normoxia, following hydroxylation and
CC       interaction with VHL. Lys-531 appears to be the principal site of
CC       ubiquitination. Clioquinol, the Cu/Zn-chelator, inhibits ubiquitination
CC       through preventing hydroxylation at Asn-802. Ubiquitinated by E3 ligase
CC       VHL. Deubiquitinated by UCHL1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q16665}.
CC   -!- PTM: Requires phosphorylation for DNA-binding. Phosphorylation at Ser-
CC       247 by CSNK1D/CK1 represses kinase activity and impairs ARNT binding.
CC       Phosphorylation by GSK3-beta and PLK3 promote degradation by the
CC       proteasome (By similarity). {ECO:0000250|UniProtKB:Q16665,
CC       ECO:0000250|UniProtKB:Q61221}.
CC   -!- PTM: The iron and 2-oxoglutarate dependent 3-hydroxylation of
CC       asparagine is (S) stereospecific within HIF CTAD domains.
CC       {ECO:0000250|UniProtKB:Q16665}.
CC   -!- PTM: Sumoylated; with SUMO1 under hypoxia. Sumoylation is enhanced
CC       through interaction with RWDD3. Both sumoylation and desumoylation seem
CC       to be involved in the regulation of its stability during hypoxia.
CC       Sumoylation can promote either its stabilization or its VHL-dependent
CC       degradation by promoting hydroxyproline-independent HIF1A-VHL complex
CC       binding, thus leading to HIF1A ubiquitination and proteasomal
CC       degradation. Desumoylation by SENP1 increases its stability amd
CC       transcriptional activity. There is a disaccord between various
CC       publications on the effect of sumoylation and desumoylation on its
CC       stability and transcriptional activity (By similarity).
CC       {ECO:0000250|UniProtKB:Q16665, ECO:0000250|UniProtKB:Q61221}.
CC   -!- PTM: In normoxia, is hydroxylated on Pro-402 and Pro-563 in the oxygen-
CC       dependent degradation domain (ODD) by EGLN1/PHD2 and EGLN2/PHD1.
CC       EGLN3/PHD3 has also been shown to hydroxylate Pro-563. The hydroxylated
CC       prolines promote interaction with VHL, initiating rapid ubiquitination
CC       and subsequent proteasomal degradation. Deubiquitinated by USP20. Under
CC       hypoxia, proline hydroxylation is impaired and ubiquitination is
CC       attenuated, resulting in stabilization (By similarity). In normoxia, is
CC       hydroxylated on Asn-802 by HIF1AN, thus abrogating interaction with
CC       CREBBP and EP300 and preventing transcriptional activation. Repressed
CC       by iron ion, via Fe(2+) prolyl hydroxylase (PHD) enzymes-mediated
CC       hydroxylation and subsequent proteasomal degradation.
CC       {ECO:0000250|UniProtKB:Q16665}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y09507; CAA70701.1; -; mRNA.
DR   EMBL; AF057308; AAD24413.1; -; mRNA.
DR   PIR; JC5809; JC5809.
DR   RefSeq; NP_077335.1; NM_024359.1.
DR   AlphaFoldDB; O35800; -.
DR   SMR; O35800; -.
DR   BioGRID; 248194; 10.
DR   IntAct; O35800; 1.
DR   MINT; O35800; -.
DR   STRING; 10116.ENSRNOP00000042230; -.
DR   PhosphoSitePlus; O35800; -.
DR   PaxDb; 10116-ENSRNOP00000042230; -.
DR   GeneID; 29560; -.
DR   KEGG; rno:29560; -.
DR   UCSC; RGD:61928; rat.
DR   AGR; RGD:61928; -.
DR   CTD; 3091; -.
DR   RGD; 61928; Hif1a.
DR   eggNOG; KOG3558; Eukaryota.
DR   InParanoid; O35800; -.
DR   OrthoDB; 5396877at2759; -.
DR   Reactome; R-RNO-1234158; Regulation of gene expression by Hypoxia-inducible Factor.
DR   Reactome; R-RNO-1234174; Cellular response to hypoxia.
DR   Reactome; R-RNO-1234176; Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha.
DR   Reactome; R-RNO-5689880; Ub-specific processing proteases.
DR   Reactome; R-RNO-8857538; PTK6 promotes HIF1A stabilization.
DR   Reactome; R-RNO-8951664; Neddylation.
DR   PRO; PR:O35800; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:1904115; C:axon cytoplasm; IEA:GOC.
DR   GO; GO:0000785; C:chromatin; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0000791; C:euchromatin; ISO:RGD.
DR   GO; GO:0031514; C:motile cilium; ISO:RGD.
DR   GO; GO:0016607; C:nuclear speck; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:RGD.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; ISO:RGD.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; ISO:RGD.
DR   GO; GO:0001216; F:DNA-binding transcription activator activity; ISO:RGD.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0001217; F:DNA-binding transcription repressor activity; ISO:RGD.
DR   GO; GO:0070888; F:E-box binding; ISO:RGD.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0042826; F:histone deacetylase binding; ISO:RGD.
DR   GO; GO:0051879; F:Hsp90 protein binding; ISO:RGD.
DR   GO; GO:0016922; F:nuclear receptor binding; ISO:RGD.
DR   GO; GO:0002039; F:p53 binding; ISO:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; ISO:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISS:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISO:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:RGD.
DR   GO; GO:0001223; F:transcription coactivator binding; ISS:UniProtKB.
DR   GO; GO:0140537; F:transcription regulator activator activity; ISO:RGD.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:RGD.
DR   GO; GO:0006953; P:acute-phase response; IEP:RGD.
DR   GO; GO:0001525; P:angiogenesis; ISO:RGD.
DR   GO; GO:0006915; P:apoptotic process; ISO:RGD.
DR   GO; GO:0019896; P:axonal transport of mitochondrion; ISS:UniProtKB.
DR   GO; GO:0001922; P:B-1 B cell homeostasis; ISO:RGD.
DR   GO; GO:0001568; P:blood vessel development; ISO:RGD.
DR   GO; GO:0048514; P:blood vessel morphogenesis; ISO:RGD.
DR   GO; GO:0030282; P:bone mineralization; ISO:RGD.
DR   GO; GO:0048593; P:camera-type eye morphogenesis; ISO:RGD.
DR   GO; GO:0003208; P:cardiac ventricle morphogenesis; ISO:RGD.
DR   GO; GO:0051216; P:cartilage development; ISO:RGD.
DR   GO; GO:0030154; P:cell differentiation; ISO:RGD.
DR   GO; GO:0071454; P:cellular response to anoxia; IEP:RGD.
DR   GO; GO:0071245; P:cellular response to carbon monoxide; IEP:RGD.
DR   GO; GO:0071279; P:cellular response to cobalt ion; IEP:RGD.
DR   GO; GO:1903928; P:cellular response to cyanide; IEP:RGD.
DR   GO; GO:0071257; P:cellular response to electrical stimulus; IEP:RGD.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IEP:RGD.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEP:RGD.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEP:RGD.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEP:RGD.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:RGD.
DR   GO; GO:0071482; P:cellular response to light stimulus; IEP:RGD.
DR   GO; GO:0071396; P:cellular response to lipid; IEP:RGD.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0071250; P:cellular response to nitrite; IEP:RGD.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISO:RGD.
DR   GO; GO:0097237; P:cellular response to toxic substance; IEP:RGD.
DR   GO; GO:1904568; P:cellular response to wortmannin; IEP:RGD.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0021987; P:cerebral cortex development; ISO:RGD.
DR   GO; GO:0002062; P:chondrocyte differentiation; ISO:RGD.
DR   GO; GO:0032963; P:collagen metabolic process; ISO:RGD.
DR   GO; GO:0002248; P:connective tissue replacement involved in inflammatory response wound healing; ISO:RGD.
DR   GO; GO:0048546; P:digestive tract morphogenesis; ISO:RGD.
DR   GO; GO:0071542; P:dopaminergic neuron differentiation; ISO:RGD.
DR   GO; GO:0051541; P:elastin metabolic process; ISO:RGD.
DR   GO; GO:0035162; P:embryonic hemopoiesis; ISO:RGD.
DR   GO; GO:0001892; P:embryonic placenta development; ISO:RGD.
DR   GO; GO:0061030; P:epithelial cell differentiation involved in mammary gland alveolus development; ISO:RGD.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISO:RGD.
DR   GO; GO:0002067; P:glandular epithelial cell differentiation; ISO:RGD.
DR   GO; GO:0002071; P:glandular epithelial cell maturation; ISO:RGD.
DR   GO; GO:0042593; P:glucose homeostasis; ISO:RGD.
DR   GO; GO:0001947; P:heart looping; ISO:RGD.
DR   GO; GO:0042541; P:hemoglobin biosynthetic process; ISO:RGD.
DR   GO; GO:0097411; P:hypoxia-inducible factor-1alpha signaling pathway; ISO:RGD.
DR   GO; GO:0035773; P:insulin secretion involved in cellular response to glucose stimulus; ISO:RGD.
DR   GO; GO:0060574; P:intestinal epithelial cell maturation; ISO:RGD.
DR   GO; GO:0001678; P:intracellular glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0006879; P:intracellular iron ion homeostasis; ISO:RGD.
DR   GO; GO:0032364; P:intracellular oxygen homeostasis; ISO:RGD.
DR   GO; GO:0061072; P:iris morphogenesis; ISO:RGD.
DR   GO; GO:0048250; P:iron import into the mitochondrion; IMP:RGD.
DR   GO; GO:0006089; P:lactate metabolic process; ISO:RGD.
DR   GO; GO:0007595; P:lactation; ISO:RGD.
DR   GO; GO:0060135; P:maternal process involved in female pregnancy; IEP:RGD.
DR   GO; GO:0097152; P:mesenchymal cell apoptotic process; ISO:RGD.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; ISO:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0030502; P:negative regulation of bone mineralization; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:0045926; P:negative regulation of growth; ISO:RGD.
DR   GO; GO:2001054; P:negative regulation of mesenchymal cell apoptotic process; ISO:RGD.
DR   GO; GO:1902894; P:negative regulation of miRNA transcription; ISO:RGD.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISO:RGD.
DR   GO; GO:0030279; P:negative regulation of ossification; ISO:RGD.
DR   GO; GO:1903377; P:negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:1903427; P:negative regulation of reactive oxygen species biosynthetic process; IMP:RGD.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; ISO:RGD.
DR   GO; GO:0070244; P:negative regulation of thymocyte apoptotic process; ISO:RGD.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; ISO:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:RGD.
DR   GO; GO:0045906; P:negative regulation of vasoconstriction; IMP:RGD.
DR   GO; GO:0001755; P:neural crest cell migration; ISO:RGD.
DR   GO; GO:0021502; P:neural fold elevation formation; ISO:RGD.
DR   GO; GO:0007405; P:neuroblast proliferation; ISO:RGD.
DR   GO; GO:0051402; P:neuron apoptotic process; ISO:RGD.
DR   GO; GO:0003151; P:outflow tract morphogenesis; ISO:RGD.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISO:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0010508; P:positive regulation of autophagy; ISO:RGD.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; ISO:RGD.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:RGD.
DR   GO; GO:0045793; P:positive regulation of cell size; IEP:RGD.
DR   GO; GO:0070101; P:positive regulation of chemokine-mediated signaling pathway; ISO:RGD.
DR   GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:RGD.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; ISO:RGD.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; ISO:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:RGD.
DR   GO; GO:0045722; P:positive regulation of gluconeogenesis; IMP:RGD.
DR   GO; GO:0046886; P:positive regulation of hormone biosynthetic process; ISO:RGD.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; ISO:RGD.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; ISO:RGD.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; ISO:RGD.
DR   GO; GO:1901526; P:positive regulation of mitophagy; ISO:RGD.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; ISO:RGD.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:1903672; P:positive regulation of sprouting angiogenesis; IMP:RGD.
DR   GO; GO:0062029; P:positive regulation of stress granule assembly; IMP:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:RGD.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IMP:RGD.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; ISO:RGD.
DR   GO; GO:0035470; P:positive regulation of vascular wound healing; IMP:RGD.
DR   GO; GO:1903715; P:regulation of aerobic respiration; ISO:RGD.
DR   GO; GO:0042127; P:regulation of cell population proliferation; ISO:RGD.
DR   GO; GO:1900037; P:regulation of cellular response to hypoxia; IEP:RGD.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:RGD.
DR   GO; GO:0006110; P:regulation of glycolytic process; ISS:UniProtKB.
DR   GO; GO:2000434; P:regulation of protein neddylation; ISS:UniProtKB.
DR   GO; GO:0070243; P:regulation of thymocyte apoptotic process; ISO:RGD.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0032909; P:regulation of transforming growth factor beta2 production; ISO:RGD.
DR   GO; GO:0014823; P:response to activity; IEP:RGD.
DR   GO; GO:0043279; P:response to alkaloid; IEP:RGD.
DR   GO; GO:0072347; P:response to anesthetic; IEP:RGD.
DR   GO; GO:0010996; P:response to auditory stimulus; IEP:RGD.
DR   GO; GO:0032025; P:response to cobalt ion; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0043627; P:response to estrogen; IEP:RGD.
DR   GO; GO:0060992; P:response to fungicide; IMP:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IEP:RGD.
DR   GO; GO:0009749; P:response to glucose; IEP:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IDA:RGD.
DR   GO; GO:0010039; P:response to iron ion; ISO:RGD.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0014850; P:response to muscle activity; ISO:RGD.
DR   GO; GO:0014074; P:response to purine-containing compound; IEP:RGD.
DR   GO; GO:0000302; P:response to reactive oxygen species; ISS:UniProtKB.
DR   GO; GO:0009651; P:response to salt stress; IEP:RGD.
DR   GO; GO:0010165; P:response to X-ray; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISO:RGD.
DR   GO; GO:0007165; P:signal transduction; ISO:RGD.
DR   GO; GO:0048771; P:tissue remodeling; IEP:RGD.
DR   GO; GO:0031929; P:TOR signaling; ISO:RGD.
DR   GO; GO:0010573; P:vascular endothelial growth factor production; ISO:RGD.
DR   GO; GO:0001944; P:vasculature development; ISO:RGD.
DR   GO; GO:0008542; P:visual learning; ISO:RGD.
DR   CDD; cd19727; bHLH-PAS_HIF1a_PASD8; 1.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; Helix-loop-helix DNA-binding domain; 1.
DR   Gene3D; 3.30.450.20; PAS domain; 2.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR001321; HIF-1_alpha.
DR   InterPro; IPR014887; HIF-1_CTAD.
DR   InterPro; IPR021537; HIF_alpha-like.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013655; PAS_fold_3.
DR   NCBIfam; TIGR00229; sensory_box; 2.
DR   PANTHER; PTHR23043; HYPOXIA-INDUCIBLE FACTOR 1 ALPHA; 1.
DR   PANTHER; PTHR23043:SF7; HYPOXIA-INDUCIBLE FACTOR 1-ALPHA; 1.
DR   Pfam; PF11413; HIF-1; 1.
DR   Pfam; PF08778; HIF-1a_CTAD; 1.
DR   Pfam; PF08447; PAS_3; 1.
DR   Pfam; PF13426; PAS_9; 1.
DR   PRINTS; PR01080; HYPOXIAIF1A.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; HLH, helix-loop-helix DNA-binding domain; 1.
DR   SUPFAM; SSF55785; PYP-like sensor domain (PAS domain); 2.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
PE   2: Evidence at transcript level;
KW   Acetylation; Activator; Cytoplasm; DNA-binding; Hydroxylation;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   S-nitrosylation; Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..825
FT                   /note="Hypoxia-inducible factor 1-alpha"
FT                   /id="PRO_0000127222"
FT   DOMAIN          17..70
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   DOMAIN          85..158
FT                   /note="PAS 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          228..298
FT                   /note="PAS 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          302..345
FT                   /note="PAC"
FT   REGION          1..401
FT                   /note="Interaction with TSGA10"
FT                   /evidence="ECO:0000250|UniProtKB:Q61221"
FT   REGION          1..30
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          21..30
FT                   /note="DNA-binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q61221"
FT   REGION          170..191
FT                   /note="Required for heterodimer formation with ARNT"
FT                   /evidence="ECO:0000250|UniProtKB:Q61221"
FT   REGION          401..602
FT                   /note="ODD"
FT   REGION          492..520
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          530..574
FT                   /note="NTAD"
FT   REGION          575..784
FT                   /note="ID"
FT   REGION          579..602
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          654..674
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          785..825
FT                   /note="CTAD"
FT   MOTIF           717..721
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        492..515
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         247
FT                   /note="Phosphoserine; by CK1"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   MOD_RES         402
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   MOD_RES         531
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   MOD_RES         550
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   MOD_RES         554
FT                   /note="Phosphothreonine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   MOD_RES         563
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   MOD_RES         575
FT                   /note="Phosphoserine; by PLK3"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   MOD_RES         588
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   MOD_RES         657
FT                   /note="Phosphoserine; by PLK3"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   MOD_RES         799
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   MOD_RES         802
FT                   /note="(3S)-3-hydroxyasparagine"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   CROSSLNK        531
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   CROSSLNK        537
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   CROSSLNK        546
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q16665"
FT   CONFLICT        12
FT                   /note="K -> NR (in Ref. 2; AAD24413)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        74
FT                   /note="D -> G (in Ref. 2; AAD24413)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        96
FT                   /note="P -> L (in Ref. 2; AAD24413)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        329
FT                   /note="D -> N (in Ref. 2; AAD24413)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        613..619
FT                   /note="ATATTAT -> TATA (in Ref. 2; AAD24413)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        708
FT                   /note="R -> K (in Ref. 2; AAD24413)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   825 AA;  92319 MW;  C4109A57F38667E9 CRC64;
     MEGAGGENEK KKMSSERRKE KSRDAARSRR SKESEVFYEL AHQLPLPHNV SSHLDKASVM
     RLTISYLRVR KLLDAGDLDI EDEMKAQMNC FYLKAPDGFV MVLTDDGDMI YISDNVNKYM
     GLTQFELTGH SVFDFTHPCD HEEMREMLTH RNGPVRKGKE QNTQRSFFLR MKCTLTSRGR
     TMNIKSATWK VLHCTGHIHV YDTSSNQPQC GYKKPPMTCL VLICEPIPHP SNIEIPLDSK
     TFLSRHSLDM KFSYCDERIT ELMGYEPEEL LGRSIYEYYH ALDSDHLTKT HHDMFTKGQV
     TTGQYRMLAK RGGYVWVETQ ATVIYNTKDS QPQCIVCVNY VVSGIIQHDL IFSLQQTESV
     LKPVESSDMK MTQLFTKVES EDTSCLFDKL KKEPDALTLL APAAGDTIIS LDFGSDDTET
     EDQQLEDVPL YNDVMFPSSN EKLNINLAMS PLPASETPKP LRSSADPALN QEVALKLESS
     PESLGLSFTM PQIQDQPASP SDGSTRQSSP EPNSPSEYCF DVDSDMVNVF KLELVEKLFA
     EDTEAKNPFS AQDTDLDLEM LAPYIPMDDD FQLRSFDQLS PLESNSPSPP SVSTVTGFQQ
     TQLQKPTITV TAATATTATT TDESKAVTKD NIEDIKILIA SPPSTQVPQE MTTAKASAYS
     GTHSRTASPD RAGKRVIEKT DKAHPRSLNL SVTLNQRNTV PEEELNPRTI ALQNAQRKRK
     MEHDGSLFQA AGIGTLLQQP GDRAPTMSLS WKRVKGYISS EQDGMEQKTI FLIPSDLACR
     LLGQSMDESG LPQLTSYDCE VNAPIQGSRN LLQGEELLRA LDQVN
//
